Disease:
Myocardial Infarction

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA No VIP available APOE E4 N/A N/A N/A
No VIP available No VIP available No VIP available CYP1A2 *1A N/A N/A N/A
No VIP available No VIP available No VIP available CYP1A2 *1C N/A N/A N/A
No VIP available No VIP available No VIP available CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2B6 *5A N/A N/A N/A
No VIP available No VIP available No VIP available CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *4 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C19 *5 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C19 *9 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C19 *13 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available No VIP available CYP2C9 *8 N/A N/A N/A
No VIP available No VIP available No VIP available VKORC1 *2 N/A N/A N/A
No VIP available No VIP available No VIP available VKORC1 *3 N/A N/A N/A
No VIP available No VIP available No VIP available VKORC1 *4 N/A N/A N/A
No VIP available CA No Variant Annotations available
rs10306114 NC_000009.11:g.125132522A>G, NC_000009.12:g.122370243A>G, NG_032900.1:g.4294A>G, NM_000962.3:c.-842A>G, NM_001271164.1:c.-842A>G, NM_001271166.1:c.-920A>G, NM_001271367.1:c.-1140A>G, NM_001271368.1:c.-890A>G, NM_080591.2:c.-842A>G, XM_005252104.1:c.-890A>G, XM_005252105.1:c.-1139A>G, XM_005252105.2:c.-1139A>G, XM_005252106.1:c.-920A>G, XM_011518875.1:c.-890A>G, XM_011518876.1:c.-4752A>G
A > G
SNP
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available CA VA
rs1062535 NC_000005.10:g.53055583G>A, NC_000005.9:g.52351413G>A, NG_008330.1:g.71258G>A, NM_002203.3:c.825G>A, NP_002194.2:p.Thr275=, NR_073103.1:n.968G>A, NR_073104.1:n.968G>A, NR_073105.1:n.968G>A, NR_073106.1:n.968G>A, NR_073107.1:n.847G>A, rs3733877
G > -
G > A
SNP
T275T
No VIP available CA No Variant Annotations available
rs1065776 NC_000003.11:g.152553628C>T, NC_000003.12:g.152835839C>T, NG_032896.2:g.5893C>T, NM_002563.4:c.57C>T, NP_002554.1:p.Ala19=
C > T
SNP
A19A
No VIP available No Clinical Annotations available VA
rs11039149 NC_000011.10:g.47255124A>G, NC_000011.9:g.47276675A>G, NG_030392.1:g.11825A>G, NM_001130102.2:c.-92-4667A>G, NM_001251934.1:c.62-4667A>G, NM_001251935.1:c.62-4667A>G, XM_005252713.1:c.-37-4056A>G, XM_005252713.2:c.-37-4056A>G, XM_005252716.1:c.-92-4667A>G, XM_005252716.2:c.-92-4667A>G, XM_005252717.1:c.-97-4662A>G, XM_005252718.1:c.-92-4667A>G, XM_005252718.2:c.-92-4667A>G, XM_011519805.1:c.-37-4056A>G, XM_011519808.1:c.-137-6117A>G, rs60920446
A > G
SNP
No VIP available CA VA
rs1126643 NC_000005.10:g.53051539C>T, NC_000005.9:g.52347369C>T, NG_008330.1:g.67214C>T, NM_002203.3:c.759C>T, NP_002194.2:p.Phe253=, NR_073103.1:n.902C>T, NR_073104.1:n.902C>T, NR_073105.1:n.902C>T, NR_073106.1:n.902C>T, NR_073107.1:n.781C>T, rs11549773, rs16880736, rs1800198
C > -
C > T
SNP
F253F
No VIP available No Clinical Annotations available VA
rs11666735 NC_000019.10:g.54885501G=, NC_000019.10:g.54885501G>A, NC_000019.9:g.55396913G=, NC_000019.9:g.55396913G>A, NM_002000.3:c.337G=, NM_002000.3:c.337G>A, NM_133269.3:c.337G=, NM_133269.3:c.337G>A, NM_133271.3:c.337G=, NM_133271.3:c.337G>A, NM_133272.3:c.301G=, NM_133272.3:c.301G>A, NM_133273.3:c.301G=, NM_133273.3:c.301G>A, NM_133274.3:c.301G=, NM_133274.3:c.301G>A, NM_133277.3:c.35-2461A>G, NM_133277.3:c.35-2461G>A, NM_133277.3:c.35-2506A>G, NM_133277.3:c.35-2506G>A, NM_133278.3:c.301G=, NM_133278.3:c.301G>A, NM_133279.2:c.337G=, NM_133279.2:c.337G>A, NP_001991.1:p.Asp113=, NP_001991.1:p.Asp113Asn, NP_579803.1:p.Asp113=, NP_579803.1:p.Asp113Asn, NP_579805.1:p.Asp113=, NP_579805.1:p.Asp113Asn, NP_579806.1:p.Asp101=, NP_579806.1:p.Asp101Asn, NP_579807.1:p.Asp101=, NP_579807.1:p.Asp101Asn, NP_579808.1:p.Asp101=, NP_579808.1:p.Asp101Asn, NP_579812.1:p.Asp101=, NP_579812.1:p.Asp101Asn, NP_579813.1:p.Asp113=, NP_579813.1:p.Asp113Asn, NT_187671.1:g.164448G=, NT_187671.1:g.164448G>A, NT_187674.1:g.171521G=, NT_187674.1:g.171521G>A, NT_187675.1:g.255740G=, NT_187675.1:g.255740G>A, NT_187676.1:g.161451G=, NT_187676.1:g.161451G>A, NT_187677.1:g.162868G=, NT_187677.1:g.162868G>A, NT_187683.1:g.159719G=, NT_187683.1:g.159719G>A, NT_187693.1:g.868027G=, NT_187693.1:g.868027G>A, NW_003571055.1:g.530732A=, NW_003571055.1:g.530732A>G, NW_003571055.2:g.530733A=, NW_003571055.2:g.530733A>G, NW_003571060.1:g.789866G=, NW_003571060.1:g.789866G>A, NW_004166865.1:g.859869G=, NW_004166865.1:g.859869G>A, XM_011526625.1:c.256G=, XM_011526625.1:c.256G>A, XM_011526626.1:c.256G=, XM_011526626.1:c.256G>A, XM_011547517.1:c.256A=, XM_011547517.1:c.256A>G, XM_011547518.1:c.256A=, XM_011547518.1:c.256A>G, XM_011547519.1:c.71-2503A>G, XM_011547519.1:c.71-2503G>A, XM_011547554.1:c.256G=, XM_011547554.1:c.256G>A, XM_011547555.1:c.256G=, XM_011547555.1:c.256G>A, XM_011547562.1:c.256G=, XM_011547562.1:c.256G>A, XM_011547563.1:c.256G=, XM_011547563.1:c.256G>A, XM_011547566.1:c.256G=, XM_011547566.1:c.256G>A, XM_011547567.1:c.256G=, XM_011547567.1:c.256G>A, XM_011547573.1:c.256G=, XM_011547573.1:c.256G>A, XM_011547574.1:c.256G=, XM_011547574.1:c.256G>A, XM_011547578.1:c.256G=, XM_011547578.1:c.256G>A, XM_011547579.1:c.256G=, XM_011547579.1:c.256G>A, XM_011547803.1:c.256G=, XM_011547803.1:c.256G>A, XM_011547804.1:c.256G=, XM_011547804.1:c.256G>A, XM_011548553.1:c.256G=, XM_011548553.1:c.256G>A, XM_011548554.1:c.256G=, XM_011548554.1:c.256G>A, XM_011548697.1:c.256G=, XM_011548697.1:c.256G>A, XM_011548698.1:c.256G=, XM_011548698.1:c.256G>A, XM_011548699.1:c.71-2461A>G, XM_011548699.1:c.71-2461G>A, XP_011524927.1:p.Asp86=, XP_011524927.1:p.Asp86Asn, XP_011524928.1:p.Asp86=, XP_011524928.1:p.Asp86Asn, XP_011545819.1:p.Asn86=, XP_011545819.1:p.Asn86Asp, XP_011545820.1:p.Asn86=, XP_011545820.1:p.Asn86Asp, XP_011545856.1:p.Asp86=, XP_011545856.1:p.Asp86Asn, XP_011545857.1:p.Asp86=, XP_011545857.1:p.Asp86Asn, XP_011545864.1:p.Asp86=, XP_011545864.1:p.Asp86Asn, XP_011545865.1:p.Asp86=, XP_011545865.1:p.Asp86Asn, XP_011545868.1:p.Asp86=, XP_011545868.1:p.Asp86Asn, XP_011545869.1:p.Asp86=, XP_011545869.1:p.Asp86Asn, XP_011545875.1:p.Asp86=, XP_011545875.1:p.Asp86Asn, XP_011545876.1:p.Asp86=, XP_011545876.1:p.Asp86Asn, XP_011545880.1:p.Asp86=, XP_011545880.1:p.Asp86Asn, XP_011545881.1:p.Asp86=, XP_011545881.1:p.Asp86Asn, XP_011546105.1:p.Asp86=, XP_011546105.1:p.Asp86Asn, XP_011546106.1:p.Asp86=, XP_011546106.1:p.Asp86Asn, XP_011546855.1:p.Asp86=, XP_011546855.1:p.Asp86Asn, XP_011546856.1:p.Asp86=, XP_011546856.1:p.Asp86Asn, XP_011546999.1:p.Asp86=, XP_011546999.1:p.Asp86Asn, XP_011547000.1:p.Asp86=, XP_011547000.1:p.Asp86Asn, rs52806707
G > A
SNP
D113N
No VIP available CA VA
rs12041331 NC_000001.10:g.156869714G>A, NC_000001.11:g.156899922G>A, NM_001080471.1:c.-9-3996G>A, XM_005245141.1:c.-168-2266G>A, XM_005245141.2:c.-168-2266G>A, XM_006711302.2:c.-168-2266G>A, XM_011509508.1:c.-164-2266G>A, XM_011509509.1:c.-107-2266G>A, XM_011509510.1:c.-107-2266G>A, XM_011509511.1:c.-168-2266G>A, XM_011509512.1:c.-494-3996G>A, rs56433638, rs60733787
G > A
SNP
No VIP available No Clinical Annotations available VA
rs12221497 NC_000011.10:g.47259102G>A, NC_000011.9:g.47280653G>A, NG_030392.1:g.15803G>A, NM_001130101.2:c.-37-78G>A, NM_001130102.2:c.-92-689G>A, NM_001251934.1:c.62-689G>A, NM_001251935.1:c.62-689G>A, NM_005693.3:c.-37-78G>A, XM_005252704.1:c.95-689G>A, XM_005252705.1:c.-37-78G>A, XM_005252706.1:c.-37-78G>A, XM_005252707.1:c.-115G>A, XM_005252707.3:c.-115G>A, XM_005252708.1:c.95-689G>A, XM_005252709.1:c.-177-78G>A, XM_005252710.1:c.-177-78G>A, XM_005252711.1:c.-597G>A, XM_005252712.1:c.-37-78G>A, XM_005252713.1:c.-37-78G>A, XM_005252713.2:c.-37-78G>A, XM_005252714.1:c.95-689G>A, XM_005252715.1:c.-37-78G>A, XM_005252715.2:c.-37-78G>A, XM_005252716.1:c.-92-689G>A, XM_005252716.2:c.-92-689G>A, XM_005252717.1:c.-97-684G>A, XM_005252718.1:c.-92-689G>A, XM_005252718.2:c.-92-689G>A, XM_006718112.1:c.-37-78G>A, XM_006718113.1:c.-37-78G>A, XM_006718114.2:c.-115G>A, XM_006718115.1:c.-177-78G>A, XM_006718116.1:c.-92-689G>A, XM_011519805.1:c.-37-78G>A, XM_011519806.1:c.-92-689G>A, XM_011519807.1:c.-92-689G>A, XM_011519808.1:c.-137-2139G>A, rs59819109
G > A
SNP
No VIP available CA VA
rs12248560 NC_000010.10:g.96521657C>T, NC_000010.11:g.94761900C>T, NG_008384.2:g.4195C>T, NM_000769.2:c.-806C>T, rs117093607, rs17442305, rs17879736
C > A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs16846673 NC_000003.11:g.151055645T>C, NC_000003.12:g.151337857T>C, NG_016019.1:g.51900A>G, NG_021244.1:g.255970T>C, NM_022788.4:c.989A>G, NM_053002.5:c.2146-12202T>C, NM_176876.2:c.989A>G, NP_073625.1:p.Glu330Gly, NP_795345.1:p.Glu330Gly, XM_005247096.1:c.2251-12202T>C, XM_006713487.2:c.2251-12202T>C, XM_011512386.1:c.2251-12202T>C, XM_011512387.1:c.2251-12202T>C, XM_011512388.1:c.2251-12202T>C, XM_011512389.1:c.2146-12202T>C, XM_011512390.1:c.2146-12202T>C, XM_011512391.1:c.1981-12202T>C, XM_011512392.1:c.1795-12202T>C, XM_011512393.1:c.2251-12202T>C, XM_011512394.1:c.2251-12202T>C, XM_011512395.1:c.2251-12202T>C, XM_011512396.1:c.676-12202T>C, XM_011512398.1:c.46-12202T>C, XM_011512399.1:c.2251-12202T>C, rs52796515, rs56915269
T > C
SNP
E330G
No VIP available No Clinical Annotations available VA
rs17708472 NC_000016.10:g.31094032G>A, NC_000016.9:g.31105353G>A, NG_011564.1:g.5924C>T, NM_001311311.1:c.173+525C>T, NM_024006.5:c.173+525C>T, NM_206824.2:c.173+525C>T, XM_005255568.1:c.173+525C>T, XM_011545943.1:c.173+525C>T, XM_011545944.1:c.173+525C>T, XM_011545945.1:c.173+525C>T, XR_243303.1:n.822+525C>T, XR_950848.1:n.961+525C>T, rs386544324
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1801131 NC_000001.10:g.11854476T>G, NC_000001.11:g.11794419T>G, NG_013351.1:g.16685A>C, NM_005957.4:c.1286A>C, NP_005948.3:p.Glu429Ala, XM_005263458.1:c.1409A>C, XM_005263458.2:c.1409A>C, XM_005263459.1:c.1355A>C, XM_005263460.1:c.1286A>C, XM_005263460.3:c.1286A>C, XM_005263461.1:c.1286A>C, XM_005263461.3:c.1286A>C, XM_005263462.1:c.1286A>C, XM_005263462.3:c.1286A>C, XM_005263463.1:c.1040A>C, XM_005263463.2:c.1040A>C, XM_011541495.1:c.1406A>C, XM_011541496.1:c.1409A>C, XP_005263515.1:p.Glu470Ala, XP_005263516.1:p.Glu452Ala, XP_005263517.1:p.Glu429Ala, XP_005263518.1:p.Glu429Ala, XP_005263519.1:p.Glu429Ala, XP_005263520.1:p.Glu347Ala, XP_011539797.1:p.Glu469Ala, XP_011539798.1:p.Glu470Ala, rs17367365, rs17857426, rs4134712
T > G
SNP
E429A
No VIP available CA VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available No Clinical Annotations available VA
rs20417 NC_000001.10:g.186650321C>G, NC_000001.11:g.186681189C>G, NG_028206.2:g.4239G>C, NM_000963.3:c.-899G>C, NR_125801.1:n.536C>G, rs11567816
C > G
SNP
No VIP available CA VA
rs20455 NC_000006.11:g.39325078A>G, NC_000006.12:g.39357302A>G, NM_001289020.1:c.2104T>C, NM_001289021.1:c.1987T>C, NM_001289024.1:c.508T>C, NM_145027.4:c.2155T>C, NP_001275949.1:p.Trp702Arg, NP_001275950.1:p.Trp663Arg, NP_001275953.1:p.Trp170Arg, NP_659464.3:p.Trp719Arg, XM_005248904.1:c.2155T>C, XM_005248904.3:c.2155T>C, XM_005248905.1:c.2104T>C, XM_005248906.1:c.1987T>C, XM_011514357.1:c.2155T>C, XM_011514358.1:c.2155T>C, XM_011514359.1:c.2155T>C, XM_011514360.1:c.1528T>C, XP_005248961.1:p.Trp719Arg, XP_005248962.1:p.Trp702Arg, XP_005248963.1:p.Trp663Arg, XP_011512659.1:p.Trp719Arg, XP_011512660.1:p.Trp719Arg, XP_011512661.1:p.Trp719Arg, XP_011512662.1:p.Trp510Arg, rs16891985, rs56572561, rs58306844
A > G
SNP
W702R
No VIP available No Clinical Annotations available VA
rs2046934 NC_000003.11:g.151057642G>A, NC_000003.12:g.151339854G>A, NG_016019.1:g.49903C>T, NG_021244.1:g.257967G>A, NM_022788.4:c.-15+742C>T, NM_053002.5:c.2146-10205G>A, NM_176876.2:c.-15+742C>T, XM_005247096.1:c.2251-10205G>A, XM_006713487.2:c.2251-10205G>A, XM_011512386.1:c.2251-10205G>A, XM_011512387.1:c.2251-10205G>A, XM_011512388.1:c.2251-10205G>A, XM_011512389.1:c.2146-10205G>A, XM_011512390.1:c.2146-10205G>A, XM_011512391.1:c.1981-10205G>A, XM_011512392.1:c.1795-10205G>A, XM_011512393.1:c.2251-10205G>A, XM_011512394.1:c.2251-10205G>A, XM_011512395.1:c.2251-10205G>A, XM_011512396.1:c.676-10205G>A, XM_011512398.1:c.46-10205G>A, XM_011512399.1:c.2251-10205G>A, rs59362541
G > A
SNP
No VIP available CA VA
rs2108622 NC_000019.10:g.15879621C>T, NC_000019.9:g.15990431C>T, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, NP_001073.3:p.Val433Met, rs116975254, rs52819608, rs57319528
C > T
SNP
V433M
No VIP available CA VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2279238 NC_000011.10:g.47260473C>T, NC_000011.9:g.47282024C>T, NG_030392.1:g.17174C>T, NM_001130101.2:c.297C>T, NM_001130102.2:c.162C>T, NM_001251934.1:c.315C>T, NM_001251935.1:c.315C>T, NM_005693.3:c.297C>T, NP_001123573.1:p.Ser99=, NP_001123574.1:p.Ser54=, NP_001238863.1:p.Ser105=, NP_001238864.1:p.Ser105=, NP_005684.2:p.Ser99=, XM_005252704.1:c.348C>T, XM_005252705.1:c.297C>T, XM_005252706.1:c.297C>T, XM_005252707.1:c.297C>T, XM_005252707.3:c.297C>T, XM_005252708.1:c.348C>T, XM_005252709.1:c.162C>T, XM_005252710.1:c.162C>T, XM_005252711.1:c.162C>T, XM_005252712.1:c.297C>T, XM_005252713.1:c.297C>T, XM_005252713.2:c.297C>T, XM_005252714.1:c.283+494C>T, XM_005252715.1:c.232+494C>T, XM_005252715.2:c.232+494C>T, XM_005252716.1:c.97+494C>T, XM_005252716.2:c.97+494C>T, XM_005252717.1:c.162C>T, XM_005252718.1:c.97+494C>T, XM_005252718.2:c.97+494C>T, XM_006718112.1:c.297C>T, XM_006718113.1:c.297C>T, XM_006718114.2:c.297C>T, XM_006718115.1:c.162C>T, XM_006718116.1:c.162C>T, XM_011519805.1:c.297C>T, XM_011519806.1:c.162C>T, XM_011519807.1:c.97+494C>T, XM_011519808.1:c.-137-768C>T, XP_005252761.1:p.Ser116=, XP_005252762.1:p.Ser99=, XP_005252763.1:p.Ser99=, XP_005252764.1:p.Ser99=, XP_005252765.1:p.Ser116=, XP_005252766.1:p.Ser54=, XP_005252767.1:p.Ser54=, XP_005252768.1:p.Ser54=, XP_005252769.1:p.Ser99=, XP_005252770.1:p.Ser99=, XP_005252774.1:p.Ser54=, XP_006718175.1:p.Ser99=, XP_006718176.1:p.Ser99=, XP_006718177.1:p.Ser99=, XP_006718178.1:p.Ser54=, XP_006718179.1:p.Ser54=, XP_011518107.1:p.Ser99=, XP_011518108.1:p.Ser54=
C > T
SNP
S99S
No VIP available No Clinical Annotations available VA
rs2301339 NC_000012.11:g.6954624G>A, NC_000012.12:g.6845460G>A, NG_009100.1:g.10250G>A, NM_001297571.1:c.697-126G>A, NM_002075.3:c.700-126G>A, NW_003871083.2:g.47044G>A, XM_005253679.1:c.700-126G>A, XM_005253680.1:c.697-126G>A, XM_005253681.1:c.702-257G>A, XM_005277751.1:c.700-126G>A, XM_005277752.1:c.697-126G>A, XM_005277753.1:c.702-257G>A, XM_011520953.1:c.700-126G>A, XM_011520954.1:c.697-126G>A, XM_011521027.1:c.*2069C>T, XM_011521028.1:c.*2069C>T, XM_011521029.1:c.*2287C>T, XM_011521030.1:c.*2220C>T, rs57171806
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2305948 NC_000004.11:g.55979558C>T, NC_000004.12:g.55113391C>T, NG_012004.1:g.17205G>A, NM_002253.2:c.889G>A, NP_002244.1:p.Val297Ile, rs386564519, rs52830740, rs56532927, rs56973163
C > T
SNP
V297I
No VIP available No Clinical Annotations available VA
rs2306283 NC_000012.11:g.21329738A>G, NC_000012.12:g.21176804A>G, NG_011745.1:g.50611A>G, NM_006446.4:c.388A>G, NP_006437.3:p.Asn130Asp, rs17389242, rs52832430, rs60767041
A > G
SNP
N130D
No VIP available No Clinical Annotations available VA
rs2824292 NC_000021.8:g.18787176G>A, NC_000021.9:g.17414857G>A, rs17833052, rs56823203
G > A
SNP
No VIP available No Clinical Annotations available VA
rs28399504 NC_000010.10:g.96522463A>G, NC_000010.11:g.94762706A>G, NG_008384.2:g.5001A>G, NM_000769.1:c.1A>G, NM_000769.2:c.1A>G, NP_000760.1:p.Met1Val
A > G
SNP
M1L/V
No VIP available No Clinical Annotations available VA
rs3093135
A > T
SNP
No VIP available No Clinical Annotations available VA
rs35599367 NC_000007.13:g.99366316G>A, NC_000007.14:g.99768693G>A, NG_008421.1:g.20493C>T, NM_001202855.2:c.522-191C>T, NM_017460.5:c.522-191C>T, XM_011515841.1:c.522-191C>T, XM_011515842.1:c.522-191C>T, rs45581939, rs62471940
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3798220 NC_000006.11:g.160961137T>C, NC_000006.12:g.160540105T>C, NG_016147.1:g.131271A>G, NM_005577.2:c.5673A>G, NP_005568.2:p.Ile1891Met, XM_005266985.1:c.5511A>G, XP_005267042.1:p.Ile1837Met, rs52832866
T > C
SNP
I1891M
No VIP available No Clinical Annotations available VA
rs4149056 NC_000012.11:g.21331549T>C, NC_000012.12:g.21178615T>C, NG_011745.1:g.52422T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, rs52816141, rs60037639
T > C
SNP
V174A
No VIP available No Clinical Annotations available VA
rs4244285 NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278
G > A
SNP
P227P
No VIP available CA No Variant Annotations available
rs428785 NC_000021.8:g.28216595C>G, NC_000021.9:g.26844276C>G, NM_006988.4:c.679G>C, NP_008919.3:p.Ala227Pro, rs17857114
C > G
SNP
A227P
No VIP available No Clinical Annotations available VA
rs4363657 NC_000012.11:g.21368722T>C, NC_000012.12:g.21215788T>C, NG_011745.1:g.89595T>C, NM_006446.4:c.1498-1331T>C, rs59042670
T > C
SNP
No VIP available CA VA
rs4961 NC_000004.11:g.2906707G>T, NC_000004.12:g.2904980G>T, NG_012037.1:g.66124G>T, NM_001119.4:c.1378G>T, NM_001286645.1:c.1378G>T, NM_014189.3:c.1378G>T, NM_014190.3:c.1378G>T, NM_176801.2:c.1378G>T, NP_001110.2:p.Gly460Trp, NP_001273574.1:p.Gly460Trp, NP_054908.2:p.Gly460Trp, NP_054909.2:p.Gly460Trp, NP_789771.1:p.Gly460Trp, XM_005247933.1:c.1378G>T, XM_005247934.1:c.1378G>T, XM_005247935.1:c.1378G>T, XM_005247936.1:c.1378G>T, XM_005247937.1:c.1378G>T, XM_005247938.1:c.1378G>T, XP_005247990.1:p.Gly460Trp, XP_005247991.1:p.Gly460Trp, XP_005247992.1:p.Gly460Trp, XP_005247993.1:p.Gly460Trp, XP_005247994.1:p.Gly460Trp, XP_005247995.1:p.Gly460Trp, rs113752720, rs52823896, rs61347248
G > T
SNP
G460W
No VIP available No Clinical Annotations available VA
rs4986893 NC_000010.10:g.96540410G>A, NC_000010.11:g.94780653G>A, NG_008384.2:g.22948G>A, NM_000769.2:c.636G>A, NP_000760.1:p.Trp212Ter, rs52827375, rs57081121
G > A
SNP
W212*
No VIP available No Clinical Annotations available VA
rs5182 NC_000003.11:g.148459395C>T, NC_000003.12:g.148741608C>T, NG_008468.1:g.48738C>T, NM_000685.4:c.573C>T, NM_004835.4:c.678C>T, NM_009585.3:c.573C>T, NM_031850.3:c.678C>T, NM_032049.3:c.660C>T, NP_000676.1:p.Leu191=, NP_004826.5:p.Leu226=, NP_033611.1:p.Leu191=, NP_114038.4:p.Leu226=, NP_114438.2:p.Leu220=, rs17231259, rs17845691, rs17858633, rs275648, rs3772606, rs56755191
C > T
SNP
L191L
No VIP available CA VA
rs5443 NC_000012.11:g.6954875C>T, NC_000012.12:g.6845711C>T, NG_009100.1:g.10501C>T, NM_001297571.1:c.822C>T, NM_002075.3:c.825C>T, NP_001284500.1:p.Ser274=, NP_002066.1:p.Ser275=, NW_003871083.2:g.47295C>T, XM_005253679.1:c.825C>T, XM_005253680.1:c.822C>T, XM_005253681.1:c.702-6C>T, XM_005277751.1:c.825C>T, XM_005277752.1:c.822C>T, XM_005277753.1:c.702-6C>T, XM_011520953.1:c.825C>T, XM_011520954.1:c.822C>T, XM_011521027.1:c.*1818G>A, XM_011521028.1:c.*1818G>A, XM_011521029.1:c.*2036G>A, XM_011521030.1:c.*1969G>A, XP_005253736.1:p.Ser275=, XP_005253737.1:p.Ser274=, XP_005277808.1:p.Ser275=, XP_005277809.1:p.Ser274=, XP_011519255.1:p.Ser275=, XP_011519256.1:p.Ser274=, rs2230334, rs3138516, rs57419337, rs6489738
C > T
SNP
S274S
No VIP available CA VA
rs5918 NC_000017.10:g.45360730T>C, NC_000017.11:g.47283364T>C, NG_008332.2:g.34523T>C, NM_000212.2:c.176T>C, NP_000203.2:p.Leu59Pro
T > C
SNP
L59P
No VIP available No Clinical Annotations available VA
rs5985 NC_000006.11:g.6318795C>A, NC_000006.12:g.6318562C>A, NG_008107.1:g.7130G>T, NM_000129.3:c.103G>T, NP_000120.2:p.Val35Leu, XM_006715010.2:c.103G>T, XM_011514342.1:c.265G>T, XP_006715073.1:p.Val35Leu, XP_011512644.1:p.Val89Leu, rs60452761
C > A
SNP
V35L
No VIP available CA VA
rs662 NC_000007.13:g.94937446T>C, NC_000007.14:g.95308134T>C, NG_008779.1:g.21439A>G, NM_000446.5:c.575A>G, NP_000437.3:p.Gln192Arg, rs11567868, rs13306697, rs17773773, rs386603940, rs60480675
T > C
SNP
Q192R
No VIP available No Clinical Annotations available VA
rs6785930 NC_000003.11:g.151056616G>A, NC_000003.12:g.151338828G>A, NG_016019.1:g.50929C>T, NG_021244.1:g.256941G>A, NM_022788.4:c.18C>T, NM_053002.5:c.2146-11231G>A, NM_176876.2:c.18C>T, NP_073625.1:p.Asn6=, NP_795345.1:p.Asn6=, XM_005247096.1:c.2251-11231G>A, XM_006713487.2:c.2251-11231G>A, XM_011512386.1:c.2251-11231G>A, XM_011512387.1:c.2251-11231G>A, XM_011512388.1:c.2251-11231G>A, XM_011512389.1:c.2146-11231G>A, XM_011512390.1:c.2146-11231G>A, XM_011512391.1:c.1981-11231G>A, XM_011512392.1:c.1795-11231G>A, XM_011512393.1:c.2251-11231G>A, XM_011512394.1:c.2251-11231G>A, XM_011512395.1:c.2251-11231G>A, XM_011512396.1:c.676-11231G>A, XM_011512398.1:c.46-11231G>A, XM_011512399.1:c.2251-11231G>A, rs11538892, rs117076892, rs386491364
G > A
SNP
N6N
No VIP available No Clinical Annotations available VA
rs6809699 NC_000003.11:g.151056598A>C, NC_000003.12:g.151338810A>C, NG_016019.1:g.50947T>G, NG_021244.1:g.256923A>C, NM_022788.4:c.36T>G, NM_053002.5:c.2146-11249A>C, NM_176876.2:c.36T>G, NP_073625.1:p.Gly12=, NP_795345.1:p.Gly12=, XM_005247096.1:c.2251-11249A>C, XM_006713487.2:c.2251-11249A>C, XM_011512386.1:c.2251-11249A>C, XM_011512387.1:c.2251-11249A>C, XM_011512388.1:c.2251-11249A>C, XM_011512389.1:c.2146-11249A>C, XM_011512390.1:c.2146-11249A>C, XM_011512391.1:c.1981-11249A>C, XM_011512392.1:c.1795-11249A>C, XM_011512393.1:c.2251-11249A>C, XM_011512394.1:c.2251-11249A>C, XM_011512395.1:c.2251-11249A>C, XM_011512396.1:c.676-11249A>C, XM_011512398.1:c.46-11249A>C, XM_011512399.1:c.2251-11249A>C, rs117564291
A > C
SNP
G12G
No VIP available No Clinical Annotations available VA
rs699 NC_000001.10:g.230845794A>G, NC_000001.11:g.230710048A>G, NG_008836.1:g.9543T>C, NM_000029.3:c.803T>C, NP_000020.1:p.Met268Thr, rs17856353, rs3182295, rs386606420, rs4714, rs61617185
A > G
SNP
M268T
No VIP available No Clinical Annotations available VA
rs7294 NC_000016.10:g.31091000C>T, NC_000016.9:g.31102321C>T, NG_011564.1:g.8956G>A, NM_001311311.1:c.*134G>A, NM_024006.5:c.*134G>A, NM_206824.2:c.*237G>A, XM_005255568.1:c.*134G>A, XM_011545816.1:c.-2191G>A, XM_011545817.1:c.-2191G>A, XM_011545818.1:c.-2191G>A, XM_011545819.1:c.-2191G>A, XM_011545820.1:c.-2191G>A, XM_011545943.1:c.*134G>A, XM_011545944.1:c.*134G>A, XM_011545945.1:c.*237G>A, XR_243303.1:n.1175G>A, XR_950848.1:n.1414G>A, rs17880624, rs59098562
C > T
SNP
No VIP available CA VA
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
No VIP available CA VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs854560 NC_000007.13:g.94946084A>T, NC_000007.14:g.95316772A>T, NG_008779.1:g.12801T>A, NM_000446.5:c.163T>A, NP_000437.3:p.Leu55Met, rs1138340, rs11567862, rs117860432, rs17434839, rs1801051, rs2228157, rs3179555, rs3202100, rs57937067
A > T
SNP
L55M
No VIP available CA No Variant Annotations available
rs9806699 NC_000015.10:g.45448194G>A, NC_000015.9:g.45740392G>A, XM_011522289.1:c.-478G>A, rs58677873
G > A
SNP
No VIP available CA No Variant Annotations available
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
Synonym
Cardiac infarction; Heart attack; Heart attack, NOS; Infarct, Myocardial; Infarction of heart; Infarction of heart, NOS; Infarction, Myocardial; Infarctions, Myocardial; Infarcts, Myocardial; MI - Myocardial infarction; Myocardial Infarct; Myocardial Infarctions; Myocardial Infarcts; Myocardial infarct; Myocardial infarction; Myocardial infarction, NOS
PharmGKB Accession Id: PA445019
External Vocabularies

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With
No related diseases are available

Publications related to Myocardial Infarction: 282

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European journal of clinical pharmacology. 2017. Wattanachai Nitsupa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement. Journal of clinical pharmacy and therapeutics. 2017. Tang X-Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. Journal of pharmaceutical sciences. 2017. Kashihara Yushi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC research notes. 2016. Kudzi William, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics. 2016. Mitropoulou Christina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical reports. 2016. Sun Xue, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016. Shendre Aditi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rotigaptide protects the myocardium and arterial vasculature from Ischaemia reperfusion injury. British journal of clinical pharmacology. 2016. Pedersen Christian M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome medicine. 2016. Bourgeois Stephane, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Platelets. 2015. Lee Ji Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease. PLoS genetics. 2015. Won Hong-Hee, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thrombosis research. 2015. Calderón-Cruz Beatriz, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European journal of clinical pharmacology. 2015. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Race influences warfarin dose changes associated with genetic factors. Blood. 2015. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell metabolism. 2015. Luzum Jasmine A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2015. Niu Xuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and drug safety. 2015. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. The pharmacogenomics journal. 2015. So D Y F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. American journal of therapeutics. 2015. Zhang Li-Jun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. European journal of clinical pharmacology. 2015. Birmingham Bruce K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2014. Wang Xia-Qin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014. Kawai Vivian K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics. 2015. Stimpfle Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015. Li Josephine H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin dosage response related pharmacogenetics in chinese population. PloS one. 2015. Li Siyue, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. Journal of clinical pharmacy and therapeutics. 2014. Karaźniewicz-Łada M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014. Leusink Maarten, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Characterizing variability in warfarin dose requirements in children using modelling and simulation. British journal of clinical pharmacology. 2014. Hamberg Anna-Karin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. The pharmacogenomics journal. 2014. Jeong E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: A potential role of CYP4F2 and GGCX polymorphisms. Thrombosis research. 2014. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. British journal of haematology. 2014. Vear Susan I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatric blood & cancer. 2014. Shaw Kaitlyn, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. Pharmacogenomics. 2014. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation. Cardiovascular genetics. 2014. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. British journal of clinical pharmacology. 2014. Floyd Christopher N, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting. Clinical pharmacology and therapeutics. 2014. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Positive Clinical Response to Clopidogrel is Independent of Paraoxonase 1 Q192R and CYP2C19 Genetic Variants. Journal of clinical pharmacology. 2014. Martínez-Quintana Efrén, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. Journal of thrombosis and thrombolysis. 2014. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenetics and genomics. 2014. Xie Cheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. European journal of clinical pharmacology. 2014. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease. PloS one. 2014. Tresukosol Damrus, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Verification of pharmacogenetics-based warfarin dosing algorithms in han-chinese patients undertaking mechanic heart valve replacement. PloS one. 2014. Zhao Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions. 2013. Viviani Anselmi Chiara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Archives of cardiovascular diseases. 2013. Mao Liu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. European journal of clinical pharmacology. 2013. Tan Sheng-Lan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Thrombosis research. 2013. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. Vascular medicine (London, England). 2013. Kadian-Dodov Daniella L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina. Circulation. Cardiovascular genetics. 2013. Kim Ho-Sook, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
PS3-4: Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting. Clinical medicine & research. 2013. Roth Joshua, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circulation. Cardiovascular genetics. 2013. DeGorter Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013. Mangravite Lara M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention. Pharmacogenetics and genomics. 2013. Park Mahn-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013. Lee Hon-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Current cardiology reports. 2013. Fisch Adam S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thrombosis research. 2013. Zhang Lanning, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The CYP2C19*17 Variant is not Independently Associated with Clopidogrel Response. Journal of thrombosis and haemostasis : JTH. 2013. Lewis Jp, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate Gene Association Study of Coronary Artery Calcification in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study. Journal of the American College of Cardiology. 2013. Ferguson Jane F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. International journal of cardiology. 2013. Wu Hongyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine. 2013. Koeth Robert A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatric cardiology. 2013. Nguyen Nguyenvu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population. Basic & clinical pharmacology & toxicology. 2013. Ozer Mahmut, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. European journal of clinical pharmacology. 2013. Subraja K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. European journal of clinical pharmacology. 2013. Rusdiana T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Variation in PEAR1 is Associated with Platelet Aggregation and Cardiovascular Outcomes. Circulation. Cardiovascular genetics. 2013. Lewis Joshua P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thrombosis research. 2013. Skov Jane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thrombosis and haemostasis. 2013. Carlquist J F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients. Die Pharmazie. 2012. Yang Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug metabolism and pharmacokinetics. 2013. Hirai Keita, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. International journal of hematology. 2012. Ma Cong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012. Bress Adam, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PloS one. 2013. Williams Paul T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability but Is Associated with Clinical Outcome after PCI. PloS one. 2013. Park Kyung Woo, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin anticoagulant therapy: a southern Italy pharmacogenetics-based dosing model. PloS one. 2013. Mazzaccara Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. European heart journal. 2012. Gong Inna Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. European journal of clinical pharmacology. 2012. Tang Xiao-Fang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine. 2012. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenetics and genomics. 2012. Wu Hongyi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. International journal of cardiology. 2012. Verschuren Jeffrey J W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. Journal of clinical pharmacy and therapeutics. 2012. Nakamura K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2012. Jneid Hani, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thrombosis and haemostasis. 2012. Kurnik D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2012. Reny J-L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Journal of thrombosis and thrombolysis. 2012. Liang Ruijuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis research. 2012. Bonello Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thrombosis research. 2012. Liang Ruijuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics. 2012. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic drug monitoring. 2012. Lee Kyung-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis. 2012. Wei Meng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 2012. Dai Ze-long, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. Journal of the American College of Cardiology. 2012. Price Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary for VDR. Pharmacogenetics and genomics. 2012. Poon Audrey H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. Circulation. Cardiovascular genetics. 2012. Paré Guillaume, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clinical therapeutics. 2012. Bejarano-Achache Idit, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics. 2012. Chan Mark Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thrombosis research. 2012. Kassimis George, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clinical pharmacology and therapeutics. 2012. Delaney J T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012. Biss Tina T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012. Moreau Caroline, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: caffeine pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and genomics. 2012. Harmsze Ankie M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circulation. Cardiovascular interventions. 2011. Jeong Young-Hoon, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clinical pharmacology : advances and applications. 2012. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nature genetics. 2012. Stahl Eli A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PloS one. 2012. Su Jia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PloS one. 2012. Papp Audrey C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. PloS one. 2012. Chen Dong-Yi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post-Myocardial Infarction Patients. Circulation. Cardiovascular interventions. 2011. Hulot Jean-Sébastien, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clinical pharmacology and therapeutics. 2011. Simon T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clinical therapeutics. 2011. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA : the journal of the American Medical Association. 2011. Cayla Guillaume, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. Journal of thrombosis and haemostasis : JTH. 2011. Campo G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics. 2011. Rideg Orsolya, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circulation. Cardiovascular genetics. 2011. Trenk Dietmar, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response. Clinical pharmacology and therapeutics. 2011. Lewis J P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in the platelet-specific collagen receptor GP6 are associated with risk of nonfatal myocardial infarction in Caucasians. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2011. Shaffer J R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy. 2011. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug metabolism and pharmacokinetics. 2011. Kato Yuya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel. Evidence-based medicine. 2011. Ramirez Andrea H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenetics and genomics. 2011. Price Elvin Tyrone, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European heart journal. 2011. Sibbing Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Journal of human genetics. 2011. Choi Jung Ran, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American heart journal. 2011. Gurbel Paul A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA : the journal of the American Medical Association. 2011. Price Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. The pharmacogenomics journal. 2011. Chan S L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation. 2011. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human genetics. 2011. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. International journal of clinical pharmacology and therapeutics. 2011. Yang J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. Journal of thrombosis and thrombolysis. 2011. You Joyce H S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nature medicine. 2011. Bouman Heleen J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. Annals of clinical and laboratory science. 2011. Moon Hee-Won, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circulation. Cardiovascular genetics. 2010. Niu Yuxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug metabolism and pharmacokinetics. 2011. Singh Onkar, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Human molecular genetics. 2010. Cha Pei-Chieng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. Journal of biomedicine & biotechnology. 2011. Kringen Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and genomics. 2010. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and genomics. 2010. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA : the journal of the American Medical Association. 2010. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010. Wallentin Lars, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and genomics. 2010. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics. 2010. Haschke-Becher Elisabeth, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. American heart journal. 2010. Tiroch Klaus A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. British journal of clinical pharmacology. 2010. Cen Han-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of thrombosis and haemostasis : JTH. 2010. Sibbing D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nature genetics. 2010. Bezzina Connie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics. 2010. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC. Cardiovascular interventions. 2010. Jeong Young-Hoon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The case for routine genotyping in dual-antiplatelet therapy. Journal of the American College of Cardiology. 2010. Damani Samir B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenetics and genomics. 2010. Sagreiya Hersh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variance in CYP2C8 and increased risk of myocardial infarction. Pharmacogenetics and genomics. 2010. Rodenburg Eline M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circulation. Cardiovascular genetics. 2010. Bailey Kristian M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thrombosis research. 2010. Wells P S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010. Sibbing Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clinical pharmacology and therapeutics. 2010. Tomlinson B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of thrombosis and haemostasis : JTH. 2010. Lubitz S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial. Journal of thrombosis and haemostasis : JTH. 2010. Maree A O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010. Blum Shany, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. The American journal of cardiology. 2010. Shiffman Dov, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clinical pharmacology and therapeutics. 2010. Perini J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clinical pharmacology and therapeutics. 2010. Bain G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The pharmacogenomics journal. 2010. Sofi F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics. 2010. Zambon Carlo-Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology. 2010. Małek Lukasz A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenetics and genomics. 2009. Zhang Jieying Eunice, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. The pharmacogenomics journal. 2009. Kaur-Knudsen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circulation. Cardiovascular genetics. 2009. Beitelshees Amber L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Molecular pharmacology. 2009. McDonald Matthew G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. American heart journal. 2009. Price Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2009. Motovska Zuzana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation. 2009. Valgimigli Marco, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2009. Keskitalo J E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clinical pharmacology and therapeutics. 2009. Fosbøl E L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. Journal of the American College of Cardiology. 2009. O'Donoghue Michelle, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome p-450 polymorphisms and response to clopidogrel. The New England journal of medicine. 2009. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine. 2009. Wallentin Lars, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature genetics. 2009. Myocardial Infarction Genetics Consortium, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nature genetics. 2009. Gudbjartsson Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS genetics. 2009. Takeuchi Fumihiko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and genomics. 2009. Huang Sheng-Wen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics and genomics. 2009. Kim Ho-Sook, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics. 2009. Borgiani Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genome-wide association study identifies three loci associated with mean platelet volume. American journal of human genetics. 2009. Meisinger Christa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of hypertension. 2009. van Wieren-de Wijer Diane B M A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood cells, molecules & diseases. 2009. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmia pharmacogenomics: methodological considerations. Current pharmaceutical design. 2009. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. The pharmacogenomics journal. 2008. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenetics and genomics. 2008. Hindorff Lucia A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and genomics. 2008. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and genomics. 2008. Peters Bas J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenetics and genomics. 2008. Marciante Kristin D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis. 2008. Giusti Betti, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clinical pharmacology and therapeutics. 2008. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC. Cardiovascular interventions. 2008. Gladding Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA : the journal of the American Medical Association. 2008. Lynch Amy I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. Journal of the American College of Cardiology. 2008. Trenk Dietmar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bivalirudin during primary PCI in acute myocardial infarction. The New England journal of medicine. 2008. Stone Gregg W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 variants and statin-induced myopathy--a genomewide study. The New England journal of medicine. 2008. SEARCH Collaborative Group, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP4F2 genetic variant alters required warfarin dose. Blood. 2008. Caldwell Michael D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2008. Sabatine Marc S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics. 2008. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of response to warfarin during initial anticoagulation. The New England journal of medicine. 2008. Schwarz Ute I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC cardiovascular disorders. 2008. Börgel Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. Pharmacogenomics. 2007. Cooke Glen E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007. Anderson Jeffrey L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. American journal of human genetics. 2007. Shen Gong-Qing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coffee, CYP1A2 genotype and risk of myocardial infarction. Genes & nutrition. 2007. El-Sohemy Ahmed, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term follow-up of the West of Scotland Coronary Prevention Study. The New England journal of medicine. 2007. Ford Ian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diuretic-gene interaction and the risk of myocardial infarction and stroke. The pharmacogenomics journal. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007. Millican Eric A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. Journal of medical genetics. 2007. Dumont Julie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Platelet genomics and the risk of atherothrombosis. Journal of thrombosis and haemostasis : JTH. 2007. Ouwehand W H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenetics and genomics. 2007. Visser Loes E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics. 2007. Nakai Kenji, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007. Li Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clinical pharmacology and therapeutics. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007. Zuccaro Piergiorgio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine. 2007. Barter Philip J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. The New England journal of medicine. 2007. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine. 2007. Wiviott Stephen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine. 2007. Kjekshus John, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. European journal of human genetics : EJHG. 2007. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA : the journal of the American Medical Association. 2007. TRIUMPH Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics. 2007. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arteriosclerosis, thrombosis, and vascular biology. 2006. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Journal of thrombosis and thrombolysis. 2006. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multiple gene polymorphisms and warfarin sensitivity. European journal of clinical pharmacology. 2006. Shikata Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. Journal of medical genetics. 2006. Li T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nature genetics. 2006. Ozaki Kouichi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; international journal of clinical chemistry. 2006. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology. 2006. Cooke Glen E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thrombosis and haemostasis. 2006. Herman Darja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circulation research. 2006. Shearman Amanda M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA : the journal of the American Medical Association. 2006. Cornelis Marilyn C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thrombosis and haemostasis. 2006. Lepäntalo Aino, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nature genetics. 2006. Helgadottir Anna, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. Journal of human genetics. 2006. Mushiroda Taisei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatric cardiology. 2006. Kosaki K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thrombosis research. 2006. Schettert Isolmar T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. International journal of cardiology. 2005. Ortlepp Jan R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thrombosis and haemostasis. 2005. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA : the journal of the American Medical Association. 2005. Lanfear David E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. The American journal of cardiology. 2005. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Aspirin resistance and a single gene. The American journal of cardiology. 2005. Jefferson Brian K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005. D'Andrea Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenetics and genomics. 2005. Holloway John W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The pharmacogenomics journal. 2005. Wadelius M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II type I receptor gene and myocardial infarction: tagging SNPs and haplotype based association study. The Beijing atherosclerosis study. Pharmacogenetics. 2004. Su Shaoyong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004. Angiolillo Dominick J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA : the journal of the American Medical Association. 2004. Cipollone Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature genetics. 2004. Helgadottir Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug safety : an international journal of medical toxicology and drug experience. 2004. Schlienger Raymond G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. American journal of hypertension. 2003. Bis Joshua C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003. Yasar Umit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. European heart journal. 2002. White H L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans. American journal of hematology. 2002. Hooper W Craig, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA : the journal of the American Medical Association. 2002. Psaty Bruce M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001. O'Connor F F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. The American journal of cardiology. 2001. Bray P F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA : the journal of the American Medical Association. 2001. Psaty B M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation. 2000. Gerdes L U, et al. PubMed